Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder
Summary
Rapid eye movement sleep behavior disorder (RBD) is the most specific prodromal marker of Parkinson's disease (PD), affecting 40-50% of PD patients. PD with RBD (RBD-PD) represents a clinically aggressive subtype characterized by more severe motor and nonmotor symptoms, prominent autonomic dysfunction, and accelerated disease progression; however, its underlying pathogenesis remains poorly understood. Here, we integrated multiplatform metabolomics and proteomics with precise clinical pheno
Content
# Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder
*Published: 2026 Mar 30*
Rapid eye movement sleep behavior disorder (RBD) is the most specific prodromal
marker of Parkinson's disease (PD), affecting 40-50% of PD patients. PD with RBD
(RBD-PD) represents a clinically aggressive subtype characterized by more severe
motor and nonmotor symptoms, prominent autonomic dysfunction, and accelerated
disease progression; however, its underlying pathogenesis remains poorly
understood. Here, we integrated multiplatform metabolomics and proteomics with
precise clinical phenotyping to delineate molecular signatures in plasma across
different PD subtypes. Our analyses demonstrated that PD patients exhibit
significant metabolic reprogramming, characterized by a shift in energy
metabolism from the tricarboxylic acid cycle toward glycolysis, a dysregulated
urea cycle, and lipid remodeling, as well as extensive activation of
inflammatory and immune responses involving the PI3K-Akt, IL-17, NF-kappaB, MAPK
and TNF signaling pathways. Notably, the RBD-PD subgroup exhibited distinctive
metabolic disturbances characterized by the accumulation of gut
microbiota-derived toxic aromatic amino acid catabolites. Importantly, these
alterations were also observed in idiopathic RBD (iRBD) patients, representing
the prodromal stage of PD. By integrating metagenomic profiles, we further
revealed that gut microbial dysbiosis in RBD-PD and iRBD drives a functional
shift away from dietary fiber fermentation and toward enhanced degradation of
protein, aromatic amino acids, glycine, and intestinal mucin glycans. This
metabolic reprogramming is associated with exacerbated oxidative stress,
neuroinflammation, and accelerated pathological progression. These findings
provide multiomic evidence that clarifies the molecular heterogeneity in PD and
highlights gut microbiota-driven dysfunction as a key contributor to both the
iRBD and RBD-PD subtypes.
DOI: 10.1038/s41392-026-02613-8